RJA
MRK icon

Raymond James & Associates’s Merck MRK Stock Holding History

Raymond James & Associates’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-54,500
Closed -$331K – 3993
2022
Q4 		$331K Buy
54,500
+19,800
+57% +$2.02M ﹤0.01% 3153
2022
Q3 		$28K Sell
34,700
-35,300
-50% -$3.15M ﹤0.01% 3765
2022
Q2 		$284K Sell
70,000
-50,900
-42% -$4.51M ﹤0.01% 3270
2022
Q1 		$184K Buy
120,900
+100
+0.1% +$7.88K ﹤0.01% 3693
2021
Q4 		$21K Buy
120,800
+7,200
+6% +$573K ﹤0.01% 4025
2021
Q3 		$93K Buy
113,600
+700
+0.6% +$53.2K ﹤0.01% 3842
2021
Q2 		$179K Sell
112,900
-22,082
-16% -$1.64M ﹤0.01% 3715
2021
Q1 		$175K Sell
134,982
-55,649
-29% -$4.1M ﹤0.01% 3647
2020
Q4 		$277K Buy
190,631
+67,072
+54% +$5.13M ﹤0.01% 3170
2020
Q3 		$125K Buy
123,559
+21,484
+21% +$1.68M ﹤0.01% 3341
2020
Q2 		$17K Buy
102,075
+4,297
+4% +$323K ﹤0.01% 3453
2020
Q1 		$24K Sell
97,778
-96,312
-50% -$7.57M ﹤0.01% 3385
2019
Q4 		$814K Sell
194,090
-1,886
-1% -$155K ﹤0.01% 2405
2019
Q3 		$489K Buy
195,976
+11,423
+6% +$915K ﹤0.01% 2662
2019
Q2 		$937K Buy
184,553
+1,153
+0.6% +$88.3K ﹤0.01% 2253
2019
Q1 		$984K Sell
183,400
-1,362
-0.7% -$102K ﹤0.01% 2212
2018
Q4 		$646K Sell
184,762
-14,672
-7% -$1.04M ﹤0.01% 2371
2018
Q3 		$598K Sell
199,434
-4,821
-2% -$307K ﹤0.01% 2590
2018
Q2 		$170K Buy
204,255
+103,123
+102% +$5.82M ﹤0.01% 3309
2018
Q1 		$37K Sell
101,132
-29,449
-23% -$1.59M ﹤0.01% 3351
2017
Q4 		$42K Sell
130,581
-59,841
-31% -$3.32M ﹤0.01% 3295
2017
Q3 		$172K Buy
190,422
+65,815
+53% +$3.99M ﹤0.01% 3095
2017
Q2 		$146K Buy
124,607
+14,043
+13% +$855K ﹤0.01% 3062
2017
Q1 		$168K Buy
110,564
+3,773
+4% +$229K ﹤0.01% 2974
2016
Q4 		$71K Buy
106,791
+88,870
+496% +$5.2M ﹤0.01% 3065
2016
Q3 		$103K Sell
17,921
-629
-3% -$36.8K ﹤0.01% 2992
2016
Q2 		$13K Buy
18,550
+7,756
+72% +$413K ﹤0.01% 2954
2016
Q1 		$5K Buy
+10,794
New +$529K ﹤0.01% 2903

Other funds holding MRK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James & Associates's MRK Position: Q3 2024 in Review

Raymond James & Associates increased its Merck (MRK) stake by 1.2% in Q3 2024, buying an estimated $13.6M and bringing the position to 9,874,714 shares worth $1.12B. The position accounts for 0.68% of the portfolio, ranked #21.

Raymond James & Associates first reported a position in MRK in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.29B in Q1 2024. 3,490 funds tracked by Wall St. Rank hold MRK as of Q3 2024.

  • Raymond James & Associates held 9,874,714 shares of Merck worth $1.12B as of Q3 2024.
  • Raymond James & Associates bought 114,080 Merck shares in Q3 2024, an estimated $13.6M.
  • Merck made up 0.68% of Raymond James & Associates's portfolio in Q3 2024, its #21 holding.
  • Raymond James & Associates first reported a position in Merck in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Merck position peaked at $1.29B in Q1 2024.
  • 3,490 funds tracked by Wall St. Rank held Merck as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.